These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

180 related articles for article (PubMed ID: 38472960)

  • 21. Molecular characterization of inflammatory myofibroblastic tumors with frequent ALK and ROS1 gene fusions and rare novel RET rearrangement.
    Antonescu CR; Suurmeijer AJ; Zhang L; Sung YS; Jungbluth AA; Travis WD; Al-Ahmadie H; Fletcher CD; Alaggio R
    Am J Surg Pathol; 2015 Jul; 39(7):957-67. PubMed ID: 25723109
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Beyond
    Farago AF; Azzoli CG
    Transl Lung Cancer Res; 2017 Oct; 6(5):550-559. PubMed ID: 29114471
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Resistance Mechanisms to Targeted Therapies in
    McCoach CE; Le AT; Gowan K; Jones K; Schubert L; Doak A; Estrada-Bernal A; Davies KD; Merrick DT; Bunn PA; Purcell WT; Dziadziuszko R; Varella-Garcia M; Aisner DL; Camidge DR; Doebele RC
    Clin Cancer Res; 2018 Jul; 24(14):3334-3347. PubMed ID: 29636358
    [No Abstract]   [Full Text] [Related]  

  • 24. Detecting ALK, ROS1, and RET fusions and the METΔex14 splicing variant in liquid biopsies of non-small-cell lung cancer patients using RNA-based techniques.
    Giménez-Capitán A; Sánchez-Herrero E; Robado de Lope L; Aguilar-Hernández A; Sullivan I; Calvo V; Moya-Horno I; Viteri S; Cabrera C; Aguado C; Armiger N; Valarezo J; Mayo-de-Las-Casas C; Reguart N; Rosell R; Provencio M; Romero A; Molina-Vila MA
    Mol Oncol; 2023 Sep; 17(9):1884-1897. PubMed ID: 37243883
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Ligation-dependent RT-PCR: a new specific and low-cost technique to detect ALK, ROS, and RET rearrangements in lung adenocarcinoma.
    Piton N; Ruminy P; Gravet C; Marchand V; Colasse É; Lamy A; Naoures Mear CL; Bibeau F; Marguet F; Guisier F; Salaün M; Thiberville L; Jardin F; Sabourin JC
    Lab Invest; 2018 Mar; 98(3):371-379. PubMed ID: 29251734
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Imaging Features and Patterns of Metastasis in Non-Small Cell Lung Cancer with
    Digumarthy SR; Mendoza DP; Lin JJ; Rooney M; Do A; Chin E; Yeap BY; Shaw AT; Gainor JF
    Cancers (Basel); 2020 Mar; 12(3):. PubMed ID: 32183422
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Multiplexed gene expression and fusion transcript analysis to detect ALK fusions in lung cancer.
    Lira ME; Kim TM; Huang D; Deng S; Koh Y; Jang B; Go H; Lee SH; Chung DH; Kim WH; Schoenmakers EF; Choi YL; Park K; Ahn JS; Sun JM; Ahn MJ; Kim DW; Mao M
    J Mol Diagn; 2013 Jan; 15(1):51-61. PubMed ID: 23246132
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Emerging oncogenic fusions other than
    Suda K; Mitsudomi T
    Transl Lung Cancer Res; 2020 Dec; 9(6):2618-2628. PubMed ID: 33489822
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Direct identification of ALK and ROS1 fusions in non-small cell lung cancer from hematoxylin and eosin-stained slides using deep learning algorithms.
    Mayer C; Ofek E; Fridrich DE; Molchanov Y; Yacobi R; Gazy I; Hayun I; Zalach J; Paz-Yaacov N; Barshack I
    Mod Pathol; 2022 Dec; 35(12):1882-1887. PubMed ID: 36057739
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Cell block-based RNA next generation sequencing for detection of gene fusions in lung adenocarcinoma: An institutional experience.
    Wei S; Talarchek JN; Huang M; Gong Y; Du F; Ehya H; Flieder DB; Patchefsky AS; Wasik MA; Pei J
    Cytopathology; 2023 Jan; 34(1):28-34. PubMed ID: 36062384
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Decoding Tumor Phenotypes for ALK, ROS1, and RET Fusions in Lung Adenocarcinoma Using a Radiomics Approach.
    Yoon HJ; Sohn I; Cho JH; Lee HY; Kim JH; Choi YL; Kim H; Lee G; Lee KS; Kim J
    Medicine (Baltimore); 2015 Oct; 94(41):e1753. PubMed ID: 26469915
    [TBL] [Abstract][Full Text] [Related]  

  • 32. ROS1 and ALK fusions in colorectal cancer, with evidence of intratumoral heterogeneity for molecular drivers.
    Aisner DL; Nguyen TT; Paskulin DD; Le AT; Haney J; Schulte N; Chionh F; Hardingham J; Mariadason J; Tebbutt N; Doebele RC; Weickhardt AJ; Varella-Garcia M
    Mol Cancer Res; 2014 Jan; 12(1):111-8. PubMed ID: 24296758
    [TBL] [Abstract][Full Text] [Related]  

  • 33. RNA-Based Multiplexing Assay for Routine Testing of Fusion and Splicing Variants in Cytological Samples of NSCLC Patients.
    Aguado C; Giménez-Capitán A; Román R; Rodríguez S; Jordana-Ariza N; Aguilar A; Cabrera-Gálvez C; Rivas-Corredor C; Lianes P; Viteri S; Moya I; Molina-Vila MA
    Diagnostics (Basel); 2020 Dec; 11(1):. PubMed ID: 33374879
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Epidermal Growth Factor Receptor (EGFR) Mutations and Anaplastic Lymphoma Kinase/Oncogene or C-Ros Oncogene 1 (ALK/ROS1) Fusions Inflict Non-Small Cell Lung Cancer (NSCLC) Female Patients Older Than 60 Years of Age.
    Ke L; Xu M; Jiang X; Sun X
    Med Sci Monit; 2018 Dec; 24():9364-9369. PubMed ID: 30580372
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Detection of Novel Tyrosine Kinase Fusion Genes as Potential Therapeutic Targets in Bone and Soft Tissue Sarcomas Using DNA/RNA-based Clinical Sequencing.
    Hasegawa N; Hayashi T; Niizuma H; Kikuta K; Imanishi J; Endo M; Ikeuchi H; Sasa K; Sano K; Hirabayashi K; Takagi T; Ishijima M; Kato S; Kohsaka S; Saito T; Suehara Y
    Clin Orthop Relat Res; 2024 Mar; 482(3):549-563. PubMed ID: 38014853
    [TBL] [Abstract][Full Text] [Related]  

  • 36. [Clinical utility of real-time fluorescent PCR for combined detection of anaplastic lymphoma kinase and c-ros oncogene 1 receptor tyrosine kinase in non-small cell lung cancer].
    Bai DY; Zhang HP; Zhong S; Suo WH; Gao DH; Ding Y; Tu JH
    Zhonghua Zhong Liu Za Zhi; 2016 Dec; 38(12):898-903. PubMed ID: 27998465
    [No Abstract]   [Full Text] [Related]  

  • 37. Comprehensive analysis of RET and ROS1 rearrangement in lung adenocarcinoma.
    Lee SE; Lee B; Hong M; Song JY; Jung K; Lira ME; Mao M; Han J; Kim J; Choi YL
    Mod Pathol; 2015 Apr; 28(4):468-79. PubMed ID: 25234288
    [TBL] [Abstract][Full Text] [Related]  

  • 38. ROS1 Fusions Rarely Overlap with Other Oncogenic Drivers in Non-Small Cell Lung Cancer.
    Lin JJ; Ritterhouse LL; Ali SM; Bailey M; Schrock AB; Gainor JF; Ferris LA; Mino-Kenudson M; Miller VA; Iafrate AJ; Lennerz JK; Shaw AT
    J Thorac Oncol; 2017 May; 12(5):872-877. PubMed ID: 28088512
    [TBL] [Abstract][Full Text] [Related]  

  • 39. RET Fluorescence In Situ Hybridization Analysis Is a Sensitive but Highly Unspecific Screening Method for RET Fusions in Lung Cancer.
    Radonic T; Geurts-Giele WRR; Samsom KG; Roemen GMJM; von der Thüsen JH; Thunnissen E; Meijssen IC; Sleddens HFBM; Dinjens WNM; Boelens MC; Weijers K; Speel EJM; Finn SP; O'Brien C; van Wezel T; Cohen D; Monkhorst K; Roepman P; Dubbink HJ
    J Thorac Oncol; 2021 May; 16(5):798-806. PubMed ID: 33588111
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Clinic-pathologic features and gene fusion pattern of ALK and ROS1 in non-small cell lung cancer show association with household coal combustion.
    Chen Y; Huang Y; Ning H; Chen X; Tan X; Ding X
    Transl Cancer Res; 2019 Sep; 8(5):2164-2174. PubMed ID: 35116966
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.